» Articles » PMID: 22502948

Grading Dermatologic Adverse Events of Cancer Treatments: the Common Terminology Criteria for Adverse Events Version 4.0

Overview
Specialty Dermatology
Date 2012 Apr 17
PMID 22502948
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Dermatologic adverse events to cancer therapies have become more prevalent and may to lead to dose modifications or discontinuation of life-saving or prolonging treatments. This has resulted in a new collaboration between oncologists and dermatologists, which requires accurate cataloging and grading of side effects. The Common Terminology Criteria for Adverse Events Version 4.0 is a descriptive terminology and grading system that can be used for uniform reporting of adverse events. A proper understanding of this standardized classification system is essential for dermatologists to properly communicate with all physicians caring for patients with cancer.

Citing Articles

Melatonin Aids in Treating Mood and Sleep Problems Resulting from Hormonal Therapy in Breast Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial.

Vaziri N, Shakourifar M, Sattari P, Sadeghi A, Sharifi M, Moghadas A Iran J Pharm Res. 2025; 23(1):e156581.

PMID: 40066115 PMC: 11892750. DOI: 10.5812/ijpr-156581.


A Review and Comparison of Immune-Checkpoint Inhibitors in the Treatment of Metastatic Uveal Melanoma.

Alam B, Akbari A, Ageed A, Duffy R J Clin Med. 2025; 14(3).

PMID: 39941557 PMC: 11818147. DOI: 10.3390/jcm14030885.


From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancers.

Watson M, Chambers P, Steventon L, Harmsworth King J, Ercia A, Shaw H BMJ Oncol. 2025; 3(1):e000430.

PMID: 39886186 PMC: 11557724. DOI: 10.1136/bmjonc-2024-000430.


The dynamic effects of nutritional status on chemotherapy-related toxicity in patients with non-Hodgkin's lymphoma.

Zhou Q, Yang H, Wang X, Wang L, Yan X, Zhang B Eur J Clin Nutr. 2025; .

PMID: 39810008 DOI: 10.1038/s41430-025-01565-6.


Is nivolumab alone or in combination with ipilimumab more effective for treating lung cancer? a meta-analysis.

Najah Q, Almosilhy N, Ghanm T Eur J Clin Pharmacol. 2024; 81(2):269-278.

PMID: 39680077 DOI: 10.1007/s00228-024-03789-0.